Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination
Direito Autoral
Objetivos para Desenvolvimento Sustentável
3. Saúde e Bem-Estar 
Coleções
Tipo
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier 12 Months
Título Alternativo
Afiliação
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil / Fundação Ataulpho de Paiva. Ri de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia em Tuberculose. Rio de Janeiro, RJ, Brasil.
University of Otago. Centre for Innovation. Dunedin, New Zealand.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
St George’s University of London. St George’s Vaccine Institute. London, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ. Brasil / Fundação Ataulpho de Paiva. Ri de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia em Tuberculose. Rio de Janeiro, RJ, Brasil.
University of Otago. Centre for Innovation. Dunedin, New Zealand.
Institut Pasteur. Unité de Génétique Mycobactérienne. Paris, France.
St George’s University of London. St George’s Vaccine Institute. London, UK.
Centre for Emergency Preparedness and Response. Health Protection Agency. Porton Down, Salisbury, UK.
Orientador
Coorientador
Membros da banca
Organizador
Coordenador
Autor institucional
Inventor
Diretor
Produtor
Roteirista
Produtora
Gravadora
Resumo
Resumo em Inglês
There is a need for an improved vaccine to better control human tuberculosis (TB), as the only currently available TB vaccine, bacillus Calmette-Guerin (BCG) delivered parenterally, offers variable levels of efficacy. Therefore, recombinant strains expressing additional antigens are being developed alongside alternative routes to parenteral delivery. There is strong evidence that BCG Moreau (RdJ) is a safe and effective vaccine in humans when given by the oral route. This study compared the efficacy of a single oral dose of wild type BCG Moreau Rio de Janeiro (RdJ), or a recombinant RdJ strain expressing Ag85B-ESAT6 fusion protein, formulated with and without lipid to enhance oral delivery, with subcutaneous BCG Danish 1331 and saline control groups in a guinea pig aerosol infection model of pulmonary tuberculosis. Protection was measured as survival at 30 weeks post-challenge and reduced bacterial load and histopathology in lungs and spleen. Results showed that a single oral dose of BCG Moreau (RdJ) or recombinant BCG Moreau (RdJ)-Ag85B-ESAT6, formulated with or without lipid, gave protection equivalent to subcutaneously delivered BCG Danish in the 30 weeks post-challenge survival study. The orally delivered vaccines gave reduced pathology scores in the lungs (three of the four formulations) and spleens (all four formulations) compared to subcutaneously delivered BCG Danish. The oral wild type BCG Moreau (RdJ) in lipid and the unformulated oral wild type BCG Moreau (RdJ) vaccine also gave statistically lower bacterial loads in the lungs and spleens, respectively, compared to subcutaneously delivered BCG Danish. This study provides further evidence to show that lipid formulation does not impair vaccine efficacy and may enhance the delivery and stability of oral vaccines intended for use in countries with poor health infrastructure. Oral delivery also avoids needles (and associated cross-infection risks) and immunisation without the need for specially trained medical professional staff.
Resumo em Espanhol
Resumo em Francês
item.page.abstractzh
Instituição titular da patente
Número do Depósito
Data de depósito
Número do Depósito da prioridade
Número da publicação
item.page.datepublicacao
item.page.dateconcessao
item.page.nrcatapatente
item.page.descriptionconcessao
item.page.dateexpiracao
🆔 Número do IPC - teste
País de depósito da patente
Palavras-chave
Palavras-chave em Inglês
Palavras-chave em Espanhol
DeCS
Documento relacionado
Versão posterior
Referência
CLARK, Simon O. et al. Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination. Vaccine, v. 28, n. 43, p. 7109-7116, 2010.
Versão anterior
DOI
10.1016/j.vaccine.2010.07.087
ISBN
ISSN
0264-410X